Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

MilliporeSigma’s ZooMAb antibodies earns first-ever ACT Label from My Green Lab

By Heather Hall | April 28, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a science and technology company, has announced that its ZooMAb recombinant antibodies platform earned Accountability, Consistency and Transparency (ACT) label from My Green Lab, a non-profit organization dedicated to creating a culture of sustainability in science.

The first-ever antibody to achieve ACT label designation, ZooMAb antibodies received the lowest Environmental Impact Factor (EIF) scores in the chemicals and reagents category.

“Helping our customers and suppliers to reduce their impact on the environment is a key part of our sustainability strategy,” said Jeffrey Whitford, head of Sustainability and Social Business Innovation, MilliporeSigma. “By showing how products rate in different categories, such as manufacturing; energy and water use; packaging; and end-of-life, the ACT label gives scientists another data point to help increase their sustainability. We are proud to be part of this program and are thrilled to achieve one of the top-ranking EIF scores for our ZooMAb antibodies.”

Unlike traditional monoclonal antibodies, or mAbs, made from identical immune cells from an animal-sourced parent cell, ZooMAb antibodies use recombinant technology. This offers an endless and consistent supply, while reducing the use of animals in research.

ZooMAb antibodies can be shipped at room temperature and then stored between 2° C and 8° C, while traditional mAbs must be shipped and stored between 2° C and 8° C, eliminating the need for specially insulated, ice-cooled containers that contribute to high packaging material consumption and transport emissions. Shipping ZooMAb antibodies, which weigh 2.5 g or about as heavy as a penny, at room temperature, allows for more opportunities to eventually ship the product in much smaller packaging, preventing the emission of around 175 metric tons of CO2 per year by 2025.

In addition to innovation and packaging, the following factors contributed to the low EIF score:

  • The manufacturing facility where the ZooMAb antibodies are produced has implemented energy, water and waste reduction measures; produced renewable energy from a wind farm; and has an environmental management system program that is ISO 14001 certified.
  • ZooMAb antibodies do not contain any Red List chemicals, CMRs, PBTs or GreenScreen Benchmark-1 chemicals.

For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

 

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Advanced Ionics secures $4.2M for decarbonization of industrial hydrogen production
The R&D 100 winner of the day: Eco-Mobility with Connected Powertrains
Argonne to host webinar exploring benefits of replacing fossil fuels with hydrogen
Curling stones: Circular, but not part of the circular economy
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars